Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Metrics to compare | BVXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBVXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.6x | −5.4x | −0.5x | |
PEG Ratio | −2.46 | −0.02 | 0.00 | |
Price/Book | 8.5x | 2.7x | 2.6x | |
Price / LTM Sales | 7.5x | 4.8x | 3.2x | |
Upside (Analyst Target) | 116.7% | 90.5% | 44.2% | |
Fair Value Upside | Unlock | 6.3% | 5.5% | Unlock |